Nyrada (ASX:NYR) Total Operating Expense : A$7.95 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada Total Operating Expense?

Nyrada's Total Operating Expense for the six months ended in Dec. 2023 was A$2.32 Mil. Nyrada's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$7.95 Mil.

Nyrada Total Operating Expense Historical Data

The historical data trend for Nyrada's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Total Operating Expense Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Total Operating Expense

6.76

5.87

5.07

9.36

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Operating Expense	Get a 7-Day Free Trial			2.81	2.26	3.73	5.63	2.32

Nyrada Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$7.95 Mil.

Nyrada Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Nyrada's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines